Market Overview

Breeze 3 data for Serada presented at 2012 North American Menopause Society Annual Meeting

Related DEPO
Dow Flirts With 19,000, S&P 500 Approaches 2,000 & NASDAQ Trading At 14-Year Highs
Depomed Prevails Against Actavis In Gralise Case

Depomed, Inc. (NASDAQ: DEPO) announced today that it is presenting two abstracts from its Phase 3 clinical trial, BREEZE 3, at this week's 23rd Annual Meeting of the North American Menopause Society (NAMS) in Orlando, FL. The data showed that Serada®, Depomed's investigational non-hormonal extended-release formulation of gabapentin, may help manage menopausal hot flashes.

"Hot flashes are a disruptive problem affecting as many as three out of four menopausal women," said JoAnn V. Pinkerton, M.D., principal investigator of BREEZE 3 and Medical Director of Midlife Health Center, Professor of Obstetrics and Gynecology and Vice Chair of Academic Affairs at the University of Virginia, Charlottesville. "At this time, hormone therapy is the only approved treatment for hot flashes, yet about 40% of symptomatic women either choose not to go on hormones or are not good candidates. The BREEZE data findings are important news for women who are looking for more choices to manage their hot flashes and the sleep issues that often accompany them."

Posted-In: News FDA

 

Related Articles (DEPO)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters